The role of serial carotid intima-media thickness assessment as a surrogate marker of atherosclerosis control in patients with recent myocardial infarction by Gacoń, Jacek et al.
74 Advances in Interventional Cardiology 2019; 15, 1 (55)
Original paper
Corresponding author: 
Anna Kabłak-Ziembicka MD, PhD, Department of Interventional Cardiology, Jagiellonian University School of Medicine, John Paul II Hospital, 
Krakow, Poland, phone: +48 12 614 3501, fax: +48 12 614 2790, e-mail: kablakziembicka@op.pl  
Received: 16.10.2018, accepted: 9.12.2018.
The role of serial carotid intima-media thickness 
assessment as a surrogate marker of atherosclerosis 
control in patients with recent myocardial infarction 
Jacek Gacoń1,2, Tadeusz Przewlocki2, Jakub Podolec2, Rafal Badacz2, Piotr Pieniazek2, Wojciech Ryniewicz3, 
Krzysztof Żmudka2, Anna Kabłak-Ziembicka2
1Department of Invasive Cardiology, E. Szczeklik’s Hospital, Tarnow, Poland 
2Department of Interventional Cardiology, Jagiellonian University School of Medicine, the John Paul II Hospital, Krakow, Poland 
3Department of Dental Prosthetics, Institute of Dentistry, Jagiellonian University School of Medicine, Krakow, Poland
Adv Interv Cardiol 2019; 15, 1 (55): 74–80
DOI: https://doi.org/10.5114/aic.2019.81705
A b s t r a c t
Introduction: Despite percutaneous coronary intervention (PCI), patients after their first myocardial infarction (MI) are at high 
risk of ischemic event recurrence. Therefore, there is a need for objective markers of adequate atherosclerosis control, independent 
of prescribed pharmacotherapy and patients’ compliance. Such a potential indicator of major adverse cerebral and coronary event 
(MACCE) risk might be change in carotid intima-media thickness (CIMT), which indicates atherosclerosis growth.
Aim: To evaluate the potential associations between CIMT changes and the incidence of MACCE and recurrent MI.
Material and methods: The CIMT assessments at baseline and during 2 follow-up visits were performed in 215 patients ad-
mitted with MI, in whom PCI was performed for an index lesion, followed by best medical treatment. The incidences of MACCE 
(cardiovascular death, recurrent MI, ischemic stroke) and new onset angina were recorded prospectively.
Results: The MACCE were recorded in 65 (30.2%) patients and angina due to coronary lesion progression (CLP) in 27 (12.5%) 
patients. Although initial CIMT values were similar in patients who suffered MACCE vs. MACCE-free patients (1.43 ±0.40 vs. 1.45 
±0.44 mm; p = 0.486), patients in whom MACCE occurred had greater annual CIMT growth as assessed at the first (0.024 ±0.12 vs. 
0.009 ±0.16 mm/year; p < 0.001) and subsequent follow-up visit (0.050 ±0.1 vs. 0.001 ±0.1 mm/year; p < 0.001), in mean 36.5 ±29.3 
and 53.3 ±37.1 months, respectively. An optimal cut-off value for annual CIMT change of > 0.003 mm/year (sensitivity: 84.5%, speci-
ficity: 49.3%) for MI plus CLP (AUC = 0.673) occurred an independent indicator of MACCE (HR = 3.00; 95% CI: 1.496–6.016), recurrent 
MI (HR = 4.59, 95% CI: 1.591–13.217), and MI plus CLP (HR = 3.50, 95% CI: 1.759–6.964).
Conclusions: Annual CIMT change might be a potentially valuable marker of atherosclerosis response to post-MI treatment.
Key words: carotid intima-media thickness, coronary artery diseases, symptom recurrence, myocardial infarction, atherosclero-
sis progression, major adverse cerebral and coronary events.
S u m m a r y
There is a need for direct indicators of atherosclerotic process slowing or growth. Baseline carotid intima-media thickness 
(CIMT) is independently associated with extent of atherosclerosis and ischemic cardiovascular events. Little is known about 
whether CIMT change may address atherosclerosis growth in individual patients, and as such whether CIMT change may be 
related to risk of major adverse cerebral and coronary event (MACCE) risk. Therefore, the present study aimed to evaluate the 
potential associations between CIMT change and the incidence of MACCE. Repeated assessment of CIMT changes might serve 
as a reflector of achieved atherosclerosis control during follow-up as it predicts the risk of major adverse cerebral and coronary 
event, recurrent myocardial infarction, and coronary disease progression.
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Introduction
Despite percutaneous coronary intervention (PCI), 
cardiac rehabilitation and best medical therapy (BMT), 
survivors of first acute myocardial infarction (MI) are 
at high risk of a recurrent MI, or a subsequent vascular 
event and cardiovascular death (CVD) [1–3].
Most studies of post-MI outcomes focus on the acute 
phase after the index event, with few data available for 
follow-up beyond the first year. Although the risk of car-
diovascular events is highest in the first year after the 
index MI, it remains remarkable in subsequent years [4]. 
The relative risk for all-cause death and cardiovascular 
outcomes (recurrent MI, CVD) is at least 30% higher than 
that in a general reference population at both 1–3 years 
and 3–5 years after MI [5]. It is true particularly for pa-
tients with additional risk factors such as diabetes, hyper- 
tension, or older age. 
Furthermore, patients despite prescribed medications 
often demonstrate poor compliance, or the dosages pre-
scribed are generally 50% or less of the dosages used in 
clinical trials [6, 7]. Both medication adherence and ther-
apeutic goals are achieved in a minority of patients [6–8].
The data reinforce the importance of secondary preven-
tion in improving long-term prognosis of post-MI patients. 
However, only a few, but indirect, prognostic tools are avail-
able, for instance assessment of the left ventricle function, 
biochemical markers of heart failure (e.g. NT-pro-BNP) or 
inflammatory process activity (e.g. hs-CRP), and occlusive 
stenotic lesions in extra-coronary vascular beds [9–12].
Yet, there is a  need for direct indicators of athero-
sclerotic process slowing or growth, independent of pre-
scribed pharmacotherapy and patients’ compliance. A po-
tential indicator of cardiovascular risk might be carotid 
intima-media thickness (CIMT). Although baseline CIMT is 
independently associated with the extent of atheroscle-
rosis and ischemic cardiovascular events [13, 14], little is 
known about whether CIMT change may address athero-
sclerosis growth in other than carotid artery territory in in-
dividual patients, and as such whether CIMT change may 
be related to risk of major adverse cerebral and coronary 
events (MACCE), recurrent MI or recurrent angina. 
Aim
Therefore, the present study aimed to evaluate the 
potential associations between CIMT change and the in-
cidence of MACCE, recurrent MI and new angina due to 
coronary lesion progression (CLP) in patients who under-
went MI.
Material and methods
This prospective study comprised 215 patients (154 
male; mean age: 63.3 ±9.8 years) admitted with recent 
MI, in whom PCI was performed for an index lesion. Of 
note, patients were treated according to contemporary 
guidelines concerning coronary intervention as well as 
best medical treatment (BMT) afterwards. 
The CIMT assessments at baseline and during at least 
2 follow-up visits were performed in all patients. The inci-
dences of MACCE, CVD, recurrent MI, ischemic stroke (IS) 
and new onset angina were recorded prospectively for 
a median of 60 months.
Inclusion criteria were as follows: age over 18 years, 
acute MI with confirmed significant (at least 50% lumen 
reduction) stenosis in an index coronary artery. 
Exclusion criteria: chronic or acute inflammatory 
status, active cancer, critical state, acute heart failure or 
with congestive heart failure in NYHA classes IV, patients 
not willing to participate in the present study, or subopti-
mal carotid artery ultrasound (e.g. massive calcifications 
enabling CIMT assessment).
According to current guidelines, patients were pre-
scribed dual antiplatelet therapy and other medications, 
including typically a  statin, β-blocker, and angiotensin 
converting enzyme inhibitors (ACEI)/angiotensin recep-
tor blockers (ARB), as per guidelines of the European So-
ciety of Cardiology [15]. 
All subjects gave their informed consent prior to enrol-
ment in accordance with the requirements of the institution-
al local Ethics Committee. The study was performed consis-
tently with the requirements of the Declaration of Helsinki.
Carotid intima-media measurement
Carotid ultrasonography was done with high-reso-
lution B-mode, color Doppler, and pulsed wave Doppler 
ultrasonography, using a  Toshiba Aplio 300 ultrasound 
machine (Toshiba Medical Systems Co) equipped with 
a 4–12-MHz linear array transducer. 
During hospital stay (baseline examination), all pa-
tients underwent measurement of the maximum carotid 
intima-media complex of the near and far walls at 3 seg-
ments, including the distal 1 cm of the common carotid 
artery, at the bifurcation, and at the level of the inter-
nal carotid artery. All measurements were expressed as 
mean maximum CIMT. 
After initial CIMT assessment, participants were fol-
lowed up twice with CIMT re-evaluation at a  mean of 
3 and 4.5 years.
The annual change in CIMT (mm/year) was calculated 
using the following equation: annual change of CIMT = 
(follow-up CIMT – baseline CIMT)/observation period in 
years.
The difference between the follow-up and baseline 
CIMT was also expressed as an absolute Δ value accord-
ing to the following equation: ΔCIMT = follow-up CIMT 
– baseline CIMT.
Follow-up period and cardiovascular events 
The clinical follow-up was continued beyond the last 
CIMT re-assessment in order to establish the potential 
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relationship between CIMT change and MACCE, recurrent 
MI and new onset of angina for a median of 60 months.
Recurrent MI was diagnosed according to contempo-
rary criteria of the European Society of Cardiology [16]. 
The diagnosis of IS was established by a neurologist to 
ensure validity. The CVD was defined as fatal IS, fatal MI, 
or other CVD (i.e., any sudden or unexpected death un-
less proven as non-cardiovascular on autopsy). The rela-
tionship between new onset angina and coronary status 
was established with coronary angiography in order to 
ensure coronary lesion progression, and exclude symp-
toms related to stenosis recurrence (restenosis or stent 
thrombosis as related to different mechanisms) [17, 18]. 
For further analysis only new angina due to CLP was tak-
en into account.
Statistical analysis
Student’s t test was used for comparison of continu-
ous variables, and the χ2 test was used to compare pro-
portions of categorical variables. Means of the analyzed 
parameters across groups were tested by analysis of vari-
ance test. Frequencies were compared by the χ2 test for 
independence.
The influence of CIMT change, clinical, and biochem-
ical factors on the incidence of the endpoints MACCE, re-
current MI, and new angina due to CLP was assessed with 
Cox univariate hazard analysis, and in cases with a p-value 
< 0.05, they were included in a multivariate stepwise Cox 
proportional hazards analysis. The results of the multivar-
iate Cox proportional hazards analysis were expressed as 
hazard ratio (HR) and 95% confidence interval (CI). Ka-
plan-Meier analysis for recurrent MI and new angina due 
to coronary lesion progression according to quartiles (A – 
lowest; D – highest quartile) of the annual CIMT change on 
the final ultrasonography was performed.
Receiver operating characteristic (ROC) curves were 
constructed to establish the best cut-off value for the an-
nual CIMT progression rate predicting risk of MACCE, re-
current MI and CLP. The area under the ROC curve (AUC) 
was calculated. Statistical analyses were performed with 
Statistica version 12.0 software (StatSoft, Inc, Tulsa, OK). 
P < 0.05 was considered statistically significant.
Results
During the median 60-month follow-up period, 
MACCE were recorded in 65 (30.2%) patients, including 
10 CVDs (9 MIs/sudden cardiac, 1 IS), 42 non-fatal MIs 
and/or 15 non-fatal ISs. Recurrent MI occurred in 12 
(5.6%) subjects during first year of follow-up, and in 26 
(12.1%) at 3 years. Additionally, angina recurrence in CCS 
classes II–III was noted in 30 (14%) patients, of which 
new angina due to CLP was observed in 20 (9.3%) pa-
tients, while angina due to in-stent restenosis was ob-
served in 10 (4.7%), as evidenced with coronary angiog-
raphy.
The detailed clinical characteristics and assessment 
depending on MACCE plus CLP incidence are summarized 
in Table I. Subjects in whom MACCE plus CLP occurred, 
as compared to the MACCE-free subgroup, were more 
often hypertensive (p = 0.026), had higher levels of se-
rum creatinine (p = 0.049) and hs-CRP (p = 0.001), and 
had a higher mean number of cardiovascular risk factors 
among hypertension, hyperlipidemia, diabetes, and ciga-
rette smoking (p = 0.058) (Table I). 
Initial CIMT values were similar in patients who suf-
fered MACCE and event-free patients (1.43 ±0.40 mm vs. 
1.45 ±0.44 mm; p = 0.486).
At first CIMT reassessment during the mean follow-up 
period of 36.5 ±29.3 months, patients in whom MACCE 
occurred had 2.7-fold greater annual CIMT growth as com-
pared to the event-free subset of patients (0.024 ±0.12 
mm vs. 0.009 ±0.16 mm/year; p < 0.001). Similar findings 
concerned the final CIMT reassessment performed during 
the mean follow-up period of 53.3 ±37.1 months (0.050 
±0.1 mm vs. 0.001 ±0.1 mm/year; p < 0.001, respectively).
In patients in whom annual CIMT change showed 
clear carotid atherosclerosis reduction (1st quartile for 
annual CIMT change), a significantly lower number of re-
current MI and new angina due to CLP was observed, as 
compared to subjects with annual CIMT changes in the 
2nd, 3rd and 4th quartiles (p = 0.008 by log rank test), and 
as compared to the 4th quartile (p < 0.001 by log rank 
test) (Figure 1). The Kaplan-Meier free-survival curves 
were 100, 97.8 and 88.4% at 1, 3 and 5 years for the 1st 
quartile, while they were 92.6, 76.6 and 61.0% for the 4th 
quartile, respectively (Figure 1).
Cox univariate regression analysis indicated several 
factors possibly associated with cardiovascular event 
risk, of which a  multivariate stepwise Cox proportional 
hazards analysis identified that risk of MACCE was asso-
ciated independently with the annual CIMT progression 
> 0.003  mm/year and serum creatinine level (Table II). 
Recurrent MI, as well as recurrent MI and new angina due 
to CLP, was associated with the annual CIMT progression 
> 0.003 mm/year, serum creatinine level, and history of 
hyperlipidaemia (Table II). 
The CIMT change was found to be an independent 
indicator of MACCE, recurrent MI and MI plus CLP with 
an optimal cut-off value of CIMT progression rate of 
> 0.003 mm/year for all study end-points (Figures 2 A–C). 
Although the annual CIMT progression rate of 0.003 mm/
year was the best predictor of MACCE, recurrent MI and 
CLP, associated with fairly good sensitivity (between 80% 
and 84.5%), it demonstrated only mild specificity, be-
tween 47% and 49.3% (AUC between 0.638 and 0.673) 
(Table III).
Discussion
In the first decade of the twenty-first century, in sur-
vivors of first MI, the cumulative incidence of death was 
Jacek Gacoń et al. Carotid intima-media thickness in patients with recent MI
77Advances in Interventional Cardiology 2019; 15, 1 (55)
12.1% at 1 year and 17.5% at 3 years, while recurrent 
MI were 5% and 8.2%, respectively [3]. In the years be-
tween 2004 and 2010, in England, in all survivors of 
a  first acute MI, the risk of a  second MI was highest 
during the first year and the cumulative risk increased 
more gradually thereafter [1]. For men, 1- and 7-year 
cumulative risks were 5.6% and 13.9%; for women, they 
were 7.2% and 16.2% [1]. Data from Swedish nation-
al registries of 108 315 patients admitted to hospital 
with a  primary MI between the years 2006 and 2011 
demonstrated that the composite endpoint of non-fatal 
MI, non-fatal IS or CVD was 18.3% during the first year 
after the index MI [2].
In the present study, the 5-year MACCE incidence was 
30.2%, and including CLP 38.6%. Recurrent MI occurred 
in 5.6% of subjects during the first year of follow-up, and 
in 12.1% at 3 years. Thus, despite the attempt to imple-
ment BMT according to guidelines, our data are consis-
tent with others in terms of MACCE incidence. 
Moreover, in patients who suffered from MACCE, we 
found a  2.7-fold greater annual CIMT progression rate 
as compared to the event-free subgroup of patients. 
Our study indicated that the annual CIMT progression 
rate of 0.003 mm/year is a sensitive marker of risk for 
MACCE, recurrent MI and CLP (sensitivity between 80% 
and 84.5%), but it demonstrated only mild specificity be-
tween 47% and 49.3% (AUC between 0.638 and 0.673).
In line with our findings, in the CLAS trial, patients 
with an annual common CIMT progression rate of 0.034 
Table I. Baseline characteristics of the study group 
Parameter Study group
(N = 215)
Subjects with 
MACCE plus CLP
(n = 83)
MACCE-free
subjects
(n = 132)
P-value
Age, mean (SD) [years] 63.3 (9.8) 63.1 (9.2) 61.3 (10.1) 0.396
Men, n (%) 154 (71.6) 59 (71) 95 (72) 0.888
Hypertension, n (%) 199 (93) 81 (98) 118 (89) 0.026
Diabetes mellitus, n (%) 102 (47) 42 (51) 60 (45) 0.462
Hyperlipidemia, n (%) 194 (90) 76 (92) 118 (89) 0.601
Smoking history, n (%) 138 (64) 57 (69) 81 (61) 0.276
Number of cardiovascular risk factors among hypertension, 
hyperlipidemia, diabetes, cigarette smoking, mean (SD)
2.93 (0.88) 3.05 (0.78) 2.86 (0.93) 0.058
Statin, n (%) 210 (98) 80 (96) 130 (98.5) 0.320
Intermittent claudication, n (%) 66 (31) 31 (37) 35 (26) 0.093
LVEF, mean (SD) % 52.8 (10.1) 52.7 (10.5) 52.3 (9.9) 0.442
hsCRP, mean (SD) [g/l] 3.12 (2.79) 3.25 (3.38) 3.06 (2.31) 0.001
Body mass index, mean (SD) [kg/m2] 27.6 (3.6) 27.2 (3.8) 27.8 (3.4) 0.494
Creatinine, mean (SD) [µmol/l] 93 (33.4) 96.9 (36.7) 90.4 (27.3) 0.049
Total cholesterol, mean (SD) [mmol/l] 4.97 (1.31) 5.07 (1.41) 4.9 (1.23) 0.486
LDL cholesterol, mean (SD) [mmol/l] 3.06 (1.1) 3.08 (1.1) 3.05 (1.1) 0.255
HDL cholesterol, mean (SD) [mmol/l] 1.19 (0.33) 1.21 (0.36) 1.17 (0.31) 0.277
Triglycerides, mean (SD) [mmol/l] 1.74 (1.43) 1.97 (1.8) 1.6 (1.1) 0.217
CAD – coronary artery disease, IS – ischemic stroke, LVEF – left ventricular ejection fraction, MI – myocardial infarction.
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Figure 1. Kaplan-Meier analysis for recurrent MI 
and new angina due to coronary lesion progres-
sion according to quartiles (A – lowest; D – highest 
quartile) of the annual CIMT change on the final 
ultrasonography (p < 0.001 for A vs. D by log-rank 
test; p = 0.008 for A vs. B, C, D by log-rank test)
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mm/year had a  2.9-fold higher CVD risk compared to 
those with a  common CIMT progression rate of 0.011 
mm/year or less [19]. 
Consistent with our results, Okayama et al. observed 
that a higher median progression rate of common CIMT 
(0.03 mm/year) was a significant determinant of MACCE 
(HR = 2.24; 95% CI: 1.25–4.03, p < 0.01) during a mean 
follow-up of 7.6 years [20]. Controversially, in the IMPROVE 
study, assessment of 15-month progression demonstrat-
ed that only the fastest CIMT max-progression was sig-
nificantly associated with risk of subsequent vascular 
events [21].
We demonstrated that when patients were stratified 
into quartiles based on the annual change in CIMT, pa-
tients in the 1st quartile had a lower probability of recur-
rent MI and CLP, as compared to patients in the other 
quartiles. This finding is in line with a  study of Hirano 
et al., including 240 patients with stable coronary artery 
disease [22]. Furthermore, Hirano et al. found that addi-
tion of the change in plaque-CIMT max in the follow-up 
period of 6 months, to conventional risk factors, resulted 
in a  greater area under the ROC curve compared with 
conventional Framingham risk factors alone (0.81 and 
0.70, respectively, p = 0.02) [22]. 
The idea of atherosclerosis tracking through serial 
CIMT assessments in patients with cardiovascular risk 
factors in the primary and the secondary prevention 
populations is very attractive as objective indicators of 
achieved atherosclerosis control would improve health 
outcome [23]. 
Many data report poor compliance and frequent 
underdosage of medications in patients discharged for 
MI. Korhonen et al. found that only 49% of the patients 
adhered (≥ 80% of days covered) to all 3 medications 
including ACE inhibitors/ARBs, β-blockers, and statins 
[24]. It is estimated that after 1, 3, and 5 years, 78, 64, 
and 58% of survivors who had started therapy were 
still receiving β-blockers, 86, 78, and 74% were receiv-
ing ACE-inhibitors, and 85, 80, and 82% were receiving 
statins, respectively [7]. Furthermore, the dosages pre-
scribed were generally 50% or less of the dosages used 
in clinical trials, and dosages did not increase during the 
observation period [7]. Patients who did not start treat-
ment shortly after discharge had a  low probability of 
starting treatment later [7]. 
Moreover, 6 months after an MI, even in patients with 
a high adherence to drug treatments (≥ 90% of days cov-
ered), blood pressure < 140/90 mm Hg, low-density lipo-
protein (LDL) < 100 mg/dl (in patients on statins), HbA
1c
 
< 7% (in treated diabetics), and smoking persistence 
were observed in 74%, 76%, 45%, and 27% of patients, 
respectively [25].
As we found in the present study, CIMT change over 
time might serve as an objective marker of atheroscle-
rosis control, and as such, without much knowledge on 
patients’ drug adherence and achieved control of cardio-
vascular risk factors, might serve as an additional tool to 
encourage lifestyle modification and motivational edu-
cation programs to reduce risk of cardiovascular events.
Study limitations
The period of CIMT measurement intervals was not 
pre-defined. Only baseline risk factor levels and medica-
tions were used for all analyses.
Conclusions
Repeated assessment of CIMT changes might serve 
as a reflector of achieved atherosclerosis control during 
follow-up as it predicts the risk of MACCE, recurrent MI, 
and coronary disease progression. 
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Table II. Multivariate stepwise Cox proportional hazards analysis. Independent risk factors of MACCE, recurrent 
MI and recurrent MI plus coronary lesion progression (CLP)
Cardiovascular event Hazard ratio 95% confidence interval P-value
MACCE:
Serum creatinine level 1.01 1.003–1.017 0.006
The annual CIMT progression > 0.003 mm/year 3.00 1.496–6.016 < 0.001
Recurrent MI:
Serum creatinine level 1.01 1.003–1.017 0.004
Hyperlipidemia 3.15 1.271–7.784 0.013
Annual CIMT progression > 0.003 mm/year 4.59 1.591–13.217 0.005
Recurrent MI plus new angina due to CLP:
Serum creatinine level 1.01 1.004–1.018 0.002
Hyperlipidemia 3.50 1.759–6.964 0.005
Annual CIMT progression > 0.003 mm/year 2.95 1.378–6.323 < 0.001
CIMT – carotid intima-media thickness, CLP – coronary lesion progression, MACCE – major adverse cerebral and coronary events, MI – myocardial infarction.
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Figure 2. Receiver operating characteristics (ROC) 
curves for annual CIMT progression rate cut-offs 
for MACCE (A), recurrent MI (B) and CAD progres-
sion (C; recurrent MI plus new angina for coronary 
lesion progression)
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Table III. Receiver operating characteristic (ROC) curves for the optimal annual CIMT progression rate cut-off 
value to predict risk of MACCE, recurrent MI and CLP
Event Annual CIMT progression 
[mm/year]
AUC 95% CI Sensitivity (%) Specificity (%)
MACCE 0.003 0.651 0.574–0.728 80.3 47
Recurrent MI 0.003 0.683 0.561–0.716 80 47.6
Recurrent MI plus CLP 0.003 0.673 0.601–0.744 84.5 49.3
CIMT – carotid intima-media thickness, CLP – coronary lesion progression, MACCE – major adverse cerebral and coronary events, MI – myocardial infarction.
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